Total plasma cfDNA methylation in pediatric kidney transplant recipients provides insight into acute allograft rejection pathophysiology.

Document Type

Article

Publication Date

6-2025

Identifier

DOI: 10.1016/j.clim.2025.110475

Abstract

Cell-free DNA (cfDNA) is a marker of organ injury and immune response. DNA methylation is an epigenetic regulator of gene expression. Here, we elucidate total plasma cfDNA methylation from kidney transplant recipients in presence versus absence of rejection. In doing so, we exploit cfDNA as a real-time biomarker to define molecular pathways of rejection. Twenty plasma cfDNA samples from pediatric kidney transplant recipients were collected at allograft biopsy. Differentially methylated cytosine residues ( >20 % methylation difference, q-value < 0.05) were identified in presence (N = 7) versus absence (N = 9) of acute rejection. Separate analyses were performed comparing borderline rejection (N = 4) to rejection and non-rejection. In rejection versus non-rejection, there were 1269 differentially methylated genes corresponding to 533 pathways. These numbers were 4-13× greater than comparisons against borderline samples. Enriched pathways between rejection and non-rejection samples were related to immune cell/inflammatory response, lipid metabolism, and tryptophan-kynurenine metabolism, suggesting differential methylation of these pathways contributes to rejection.

Journal Title

Clinical immunology (Orlando, Fla.)

Volume

275

First Page

110475

Last Page

110475

MeSH Keywords

Humans; Graft Rejection; Kidney Transplantation; DNA Methylation; Child; Cell-Free Nucleic Acids; Female; Male; Adolescent; Biomarkers; Child, Preschool

PubMed ID

40107586

Keywords

Acute allograft rejection; Epigenetics; Kidney transplant; Methylation; Pediatrics; cfDNA

Link to Full Text
Library Record

Share

COinS